Connect your AI

Denali Therapeutics Inc. DNLI Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

Viking TherapeuticsVKTX

7.5×+4.3×

uniQureQURE

6.8×-10.2×

BiogenBIIB

1.4×+0.3×

Dyne Therapeutics, Inc.DYN

3.5×+1.7×

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.93B+54.2%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

market cap/total stockholders equity=3.3×

Based on the most recent quarter.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s price / book?: Denali Therapeutics Inc. (DNLI) reported price / book of 3.3× in Q1 2026.
How has Denali Therapeutics Inc.'s price / book changed year-over-year?: Denali Therapeutics Inc.'s price / book increased by 87.0% year-over-year, from 1.8× to 3.3×.
What is the long-term trend for Denali Therapeutics Inc.'s price / book?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s price / book has grown at a -22.1% compound annual growth rate (CAGR), from 8.9× to 2.5×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.